scispace - formally typeset
X

Xionghui Mao

Researcher at Harbin Medical University

Publications -  24
Citations -  497

Xionghui Mao is an academic researcher from Harbin Medical University. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Cancer. The author has an hindex of 9, co-authored 21 publications receiving 261 citations.

Papers
More filters
Journal ArticleDOI

Antitumor activity of polysaccharides from Lepista sordida against laryngocarcinoma in vitro and in vivo.

TL;DR: MTT and lactate dehydrogenase (LDH) assays indicated that three acidic polysaccharides, namely LSPb1, L SPb2 and LSPc1, possessed more potent antiproliferative effect on human laryngocarcinoma Hep-2 cells than neutral poly Saccharide LSPa1 in a dose- and time-dependent manner.
Journal ArticleDOI

HPV + HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity.

TL;DR: It is found that HPV+HNSCC exosomes were able to transform macrophages into the M1 phenotype, which subsequently increased the radiosensitivity of HNSCC, and miR-9 may be used as a potential treatment for H NSCC.
Journal ArticleDOI

miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression

TL;DR: Meng et al. as discussed by the authors explored the biological effects of miR-217 on laryngeal cancer and found that miR217 inhibited multiple metastatic traits, including cell migration, invasion, proliferation, apoptosis, and EMT, as well as angiogensis.
Journal ArticleDOI

IL-6 Induced M1 Type Macrophage Polarization Increases Radiosensitivity in HPV Positive Head and Neck Cancer

TL;DR: M1 macrophages represent an important tissue microenvironment factor with implications for HNSC treatment efficacy and may prove valuable as a biomarker of radiation sensitivity.
Journal ArticleDOI

Long non-coding RNA AFAP1-AS1/miR-320a/RBPJ axis regulates laryngeal carcinoma cell stemness and chemoresistance.

TL;DR: The results suggest that AFAP1‐AS1 can serve as a prognostic biomarker in laryngeal carcinoma and that miR‐320a has the potential to improve standard therapeutic approaches to the disease, especially for cases in which cancer cell stemness and drug resistance present significant barriers to effective treatment.